A dual-label immunofluorometric assay for human osteocalcin

Area of Science:

• Biochemistry
• Endocrinology
• Assay Development

Background:

• Circulating human osteocalcin (hOC) exists primarily as intact (1-49) and N-terminal midfragment (N-mid, 1-43/1-44) forms.
• Accurate quantification of these hOC forms is crucial for understanding bone metabolism and disease.
• Existing assays may not effectively differentiate between the intact and N-mid forms of hOC.

Purpose of the Study:

• To develop and validate a dual-label assay for simultaneous measurement of intact and N-mid hOC in serum.
• To compare hOC levels in premenopausal and postmenopausal women, with and without hormone replacement therapy (HRT).

Main Methods:

• Development of a time-resolved fluorescence dual-label assay using three specific monoclonal antibodies (MAbs).
• MAbs 2H9 (capture), 6F9 (Europium-labeled), and 3G8 (Terbium-labeled) were employed to differentiate hOC forms.
• Assay validation involved testing antibody binding with purified and modified hOC, and comparison with single-label assays.

Main Results:

• The dual-label assay demonstrated good agreement with single-label assays for total (intact + N-mid) hOC (r=0.96) and intact hOC (r=0.81).
• Serum levels of intact + N-mid hOC were 6.2±2.1 ng/ml (premenopausal), 13.9±4.9 ng/ml (postmenopausal, no HRT), and 7.5±3.4 ng/ml (postmenopausal, with HRT).
• Serum levels of intact hOC were 4.8±1.4 ng/ml (premenopausal), 9.8±2.9 ng/ml (postmenopausal, no HRT), and 5.3±2.1 ng/ml (postmenopausal, with HRT).

Conclusions:

• The developed dual-label assay reliably measures intact and N-mid hOC forms in human serum.
• Distinct differences in hOC levels were observed between premenopausal and postmenopausal women, influenced by HRT.
• Further research is needed to determine if hOC forms and their proportions can predict or monitor bone diseases.